Navigation Links
Pharmazz, Inc. advances its product pipeline for the treatment of stroke, strengthens patent portfolio and presents hemorrhagic shock data at the American Heart Association
Date:11/30/2016

NAPERVILLE, Ill., Nov. 30, 2016 /PRNewswire/ -- Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. Results of the human safety and pharmacokinetics of PMZ-2010 were presented at the American Heart Association Scientific Sessions 2016. Abstract titled "Human pharmacokinetics of centhaquin citrate, a novel resuscitative agent" and "Centhaquin citrate improves cerebral blood flow and reduces oxidative stress following hemorrhagic shock in rats" were presented. Pharmazz is developing PMZ-2010 (centhaquin) as a resuscitative agent having a unique property of increasing blood pressure and cardiac output, and decreasing vascular resistance in hemorrhagic shock. In addition, the company is developing PMZ-1620 which is a neuroregenerative agent that produces neurogenesis and angiogenesis in the damaged area of the brain by stimulating endogenous regenerative mechanisms. A human study (CTRI/2016/11/007509) has been initiated to determine the safety and tolerance of PMZ-1620. The company also announced that a Notice of Issuance was received from the US Patent and Trademark Office, for the patent application regarding "Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist" United States Patent No. 9,493,524 issued on November 15th 2016. In addition, the company declared issuance of patent titled "Method and composition for treating diabetic ketoacidosis" by Canadian Intellectual Property Office on November 29th 2016. In patients with diabetic ketoacidosis high levels of ketone can be dangerously harmful to the body; PMZ-2123 when used with insulin can rapidly lower the blood ketone levels.

"We are pleased to have been granted these Notice of Issuance from the US and Canadian Patent Office," said Dr. Anil Gulati, Inventor and founder of Pharmazz. He added that, "Advancing PMZ-1620 towards human studies is a significant step for the company to develop a novel product that will provide a new simple option for the treatment of patients with (stroke) cerebral ischemia."

About Pharmazz, Inc. 
Pharmazz, Inc. is a privately-held company engaged in the development of novel products in the area of critical care medicine. Additional information may be found on the Company's website, www.pharmazz.com.  

Forward-Looking Statements 
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties including the risk that Pharmazz, Inc. cannot execute its business plan for lack of capital or other resources, distribution, partnering or licensing/acquisition opportunities. Actual events or results may differ materially from those projected in any of such statements due to various factors. Any of these risks could cause Pharmazz, Inc. or its industry's, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this presentation. Except as required by applicable law Pharmazz, Inc. does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact 
Pharmazz, Inc.  
Shruti Gulati 
630-780-6087 
shruti.gulati@pharmazz.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmazz-inc-advances-its-product-pipeline-for-the-treatment-of-stroke-strengthens-patent-portfolio-and-presents-hemorrhagic-shock-data-at-the-american-heart-association-300370066.html


'/>"/>
SOURCE Pharmazz, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Pharmaceutical Excipients Market 2016-2021 - Advances in Nanotechnology Imparting New Functions to Pharmaceutical Excipients - Research and Markets
2. Leksell Gamma Knife Society Convenes in Amsterdam to Discuss Latest Clinical and Technological Advances in Radiosurgery
3. Color Genomics Advances Precision Medicine with New Test for Hereditary Cancers
4. Janssen Disease Interception Unit Advances A Growing Venture Portfolio Focused On Intercepting Diseases Prior To Onset
5. AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
6. American Humane Association: Congressional Briefing Outlines Advances And Pioneering Research On Cancer In Children And Animals
7. RBELL Medical Advances Complex Wound Care
8. New High Intensity Focused Ultrasound (HIFU) Advances Treatment for Prostate Cancer
9. New PeriGen White Papers Depict Basic Physiology of Fetal Heart Control and Advances in EFM
10. Advances in Medical Manufacturing
11. Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
Breaking Medicine News(10 mins):